Shanghai, China, August 22, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject has been dosed in the US for HLX43-NSCLC201, a phase 2 international muticenter clinical trial of HLX43, its innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Henlius is vigorously advancing the global development of HLX43, with an international multi-region phase 2 clinical trial initiated in China, the US, Australia, and Japan. At present, no PD-L1 targeting ADC has been approved for marketing globally.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed anti-PD-1 monoclonal antibody (mAb) serplulimab was recently prescribed for the first time in both Europe and India. This milestone marks that this Chinese innovative biologic is now in clinical use in Europe as well as the world’s most populous country, further accelerating the global accessibility of innovative biologics.

HONG KONG, August 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").

(August 18, 2025, Shanghai, China）— On August 18, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) announced that its self-developed innovative drug Luvometinib Tablets(Chinese trade name:复迈宁^®; the “Drug”) has gained Breakthrough Therapy Designation by the Saudi Food and Drug Authority(SFDA) for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms. This milestone marks the acceleration of the Drug’s registration and commercialization process in Saudi Arabia.

Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum"). As agreed, Henlius will obtain the development and exclusive commercialization rights for the innovative HER2-targeted antibody-drug conjugate (ADC) GQ1005 in China and certain overseas markets. The drug candidate, currently in phase 3 clinical development, is being evaluated for HER2-positive breast cancer.

Shanghai, China, August 13, 2025 – Henlius (2696.HK) announced that the New Drug Application (NDA) for the HLX04-O, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the company and Essex, for the treatment of wet (neovascular) age-related macular degeneration(wAMD) has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (NMPA). As of now, none of the bevacizumab products marketed in Chinese mainland has been approved for the treatment of wAMD.

On August 13, 2025 (Pacific Time), the World Conference on Lung Cancer (WCLC) 2025 has officially unveiled the list of accepted abstracts. Ten studies on Henlius' innovative PD-L1 ADC HLX43, anti-EGFR mAb HLX07 and anti–PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) have been selected for multiple sessions, including oral presentations, poster tours, and poster presentations. Among these, 4 will be featured as oral presentations and 2 as poster tours. The selected studies span first-line treatment for non-squamous non–small cell lung cancer (nsNSCLC), squamous non–small cell lung cancer (sqNSCLC), and extensive-stage small cell lung cancer (ES-SCLC). In addition, innovative therapies are being actively promoted to explore the therapeutic potential of immunotherapy in a wide range of populations, including the perioperative setting for patients with NSCLC and patients with brain metastases.

(August 11, 2025, Shanghai, China) On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc. (Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR and Macau SAR.

HO CHI MINH CITY, Vietnam, August 7, 2025 -- Club Med, the pioneer in premium all-inclusive holidays for 75 years, and PT Grahatama Kreasi baru (GKB), a leading Indonesian hospitality developer, announced the signing of a Hotel Management Agreement that heralds the highly anticipated Club Med Manado in North Sulawesi, adding another jewel to the East and Southeast Asia region portfolio.